Puma Biotechnology, Inc. (PBYI) shareholders
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alan H. Auerbach | 8,648,958 | 16.00% | 13D (active) amendment | Oct 4, 2026 |
| Anders Hove | 3,940,052 | 8.00% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 2,779,452 | 5.60% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PBYI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Acorn Capital Advisors, LLC | 4,131,299 | 8.00% | $33.50M | – | 9.14% |
| BlackRock, Inc. | 3,804,736 | 7.37% | $30.86M | +205,784 | 0.00% |
| American Century Companies Inc | 2,319,996 | 4.49% | $18.82M | +403,650 | 0.01% |
| Acadian Asset Management LLC | 2,053,523 | 3.98% | $16.65M | +11,764 | 0.02% |
| Renaissance Technologies LLC | 1,836,213 | 3.56% | $14.89M | −106,200 | 0.02% |
| Vanguard Capital Management LLC | 1,835,643 | 3.56% | $14.89M | +17,962 | 0.00% |
| Vanguard Portfolio Management LLC | 1,825,599 | 3.54% | $14.81M | +90,950 | 0.00% |
| Lsv Asset Management | 1,617,981 | 3.13% | $13.12M | +435,113 | 0.02% |
| Dimensional Fund Advisors LP | 1,518,014 | 2.94% | $12.31M | +81,908 | 0.00% |
| Geode Capital Management, LLC | 1,339,405 | 2.59% | $10.86M | +322,063 | 0.00% |
| O'Shaughnessy Asset Management, LLC | 1,123,783 | 2.18% | $9.11M | −14,386 | 0.04% |
| State Street Corp | 952,165 | 1.84% | $7.72M | +34,575 | 0.00% |
| Kennedy Capital Management LLC | 873,253 | 1.69% | $7.08M | −16,348 | 0.13% |
| Bridgeway Capital Management, LLC | 791,616 | 1.53% | $6.42M | +16,275 | 0.11% |
| Ritholtz Wealth Management | 749,798 | 1.45% | $6.08M | −24,510 | 0.09% |
| Aqr Capital Management LLC | 725,192 | 1.40% | $5.88M | −75,002 | 0.00% |
| Goldman Sachs Group Inc | 669,156 | 1.30% | $5.43M | −563 | 0.00% |
| Northern Trust Corp | 652,386 | 1.26% | $5.29M | +10,633 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 642,946 | 1.25% | $5.21M | −139,852 | 0.01% |
| UBS Group AG | 636,761 | 1.23% | $5.16M | +102,534 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 161 | 39M | 74.9% | 22 / 60 | 52 / 15 | 3M | 2M |
| Q1 2026 | 157 | 38M | 73.3% | 29 / 61 | 38 / 18 | 8M | 2M |
| Q4 2025 | 151 | 35M | 68.5% | 33 / 51 | 39 / 14 | 4M | 3M |
| Q3 2025 | 132 | 34M | 66.6% | 23 / 44 | 35 / 12 | 5M | 3M |
| Q2 2025 | 121 | 33M | 63.7% | 22 / 42 | 32 / 16 | 5M | 2M |
| Q1 2025 | 116 | 30M | 58.9% | 25 / 44 | 25 / 20 | 3M | 2M |
| Q4 2024 | 112 | 30M | 57.2% | 28 / 46 | 21 / 15 | 6M | 5M |
| Q3 2024 | 100 | 30M | 57.7% | 19 / 33 | 23 / 17 | 6M | 4M |
| Q2 2024 | 99 | 31M | 60.0% | 26 / 33 | 26 / 20 | 6M | 6M |
| Q1 2024 | 93 | 31M | 60.1% | 20 / 36 | 26 / 9 | 8M | 4M |
| Q4 2023 | 82 | 27M | 52.3% | 19 / 29 | 15 / 6 | 4M | 2M |
| Q3 2023 | 69 | 26M | 49.8% | 6 / 20 | 23 / 5 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
184 funds held PBYI in Q2 2026, 37% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PBYI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Avantis U.S. Small Cap Value ETF | 1,924,360 | 3.73% | $13.80M | 0.05% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,343,121 | 2.60% | $10.89M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,177,097 | 2.28% | $9.55M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 777,390 | 1.51% | $6.16M | 0.03% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 540,434 | 1.05% | $4.38M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 484,010 | 0.94% | $3.84M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 437,741 | 0.85% | $3.55M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 336,311 | 0.65% | $2.73M | 0.02% | Jun 30, 2026 |
| Small Cap Value Fund | 267,945 | 0.52% | $2.17M | 0.32% | Jun 30, 2026 |
| Small-Cap Value Fund | 249,200 | 0.48% | $2.02M | 0.59% | Jun 30, 2026 |
| Tax-Managed U.S. Mid & Small Cap Fund | 248,058 | 0.48% | $1.97M | 0.10% | Jul 31, 2026 |
| U.S. Targeted Value Portfolio | 221,297 | 0.43% | $1.75M | 0.01% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 221,052 | 0.43% | $1.58M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 220,843 | 0.43% | $1.75M | 0.01% | Jul 31, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 220,316 | 0.43% | $1.79M | 0.07% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alan H. Auerbach | President and CEO, Director, 10% owner | 7,261,671 | 14.07% | Jul 8, 2026 |
| Maximo F. Nougues | Chief Financial Officer | 230,637 | 0.45% | Jul 8, 2026 |
| Douglas M. Hunt | See Remarks | 196,841 | 0.38% | Jul 8, 2026 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | 156,792 | 0.30% | Feb 11, 2025 |
| Michael Patrick Miller | Director | 66,000 | 0.13% | Nov 13, 2026 |
| Troy Edward Wilson | Director | 55,300 | 0.11% | Sep 16, 2026 |
| Alessandra Cesano | Director | 118,850 | 0.23% | Sep 16, 2026 |
| Allison Dorval | Director | 90,780 | 0.18% | Jun 15, 2026 |
| Adrian Senderowicz | Director | 27,000 | 0.05% | Jun 15, 2026 |
| Brian M. Stuglik | Director | 113,858 | 0.22% | Jun 15, 2026 |
| Jay M. Moyes | Director | 58,322 | 0.11% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Patrick Miller Director | Nov 11, 2026 | Sale | −15,000 | $8.10 | $121.46K | 66,000 |
| Alessandra Cesano Director | Sep 14, 2026 | Option exercise | +50,000 | $2.93 | $146.50K | 118,850 |
| Alessandra Cesano Director | Sep 14, 2026 | Sale(10b5-1 plan) | −62,150 | $9.12 | $566.81K | 56,700 |
| Troy Edward Wilson Director | Sep 14, 2026 | Sale(10b5-1 plan) | −5,000 | $9.10 | $45.50K | 54,750 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jul 6, 2026 | Sale(10b5-1 plan) | −44,058 | $8.26 | $363.92K | 7,261,671 |
| Douglas M. Hunt See Remarks | Jul 6, 2026 | Sale(10b5-1 plan) | −8,460 | $8.26 | $69.88K | 196,841 |
| Maximo F. Nougues Chief Financial Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −9,386 | $8.26 | $77.53K | 230,637 |
| Allison Dorval Director | Jun 12, 2026 | Sale(10b5-1 plan) | −11,610 | $7.20 | $83.59K | 90,780 |
| Adrian Senderowicz Director | Jun 12, 2026 | Sale(10b5-1 plan) | −27,000 | $7.20 | $194.40K | 27,000 |
| Jay M. Moyes Director | Jun 12, 2026 | Sale(10b5-1 plan) | −22,000 | $7.22 | $158.84K | 58,322 |
| Brian M. Stuglik Director | Jun 12, 2026 | Sale(10b5-1 plan) | −8,100 | $7.20 | $58.32K | 113,858 |
| Troy Edward Wilson Director | Jun 12, 2026 | Sale(10b5-1 plan) | −10,800 | $7.20 | $77.76K | 59,750 |
| Allison Dorval Director | Jun 11, 2026 | Award | +27,000 | – | – | 102,390 |
| Adrian Senderowicz Director | Jun 11, 2026 | Award | +27,000 | – | – | 54,000 |
| Jay M. Moyes Director | Jun 11, 2026 | Award | +27,000 | – | – | 80,322 |
| Brian M. Stuglik Director | Jun 11, 2026 | Award | +27,000 | – | – | 121,958 |
| Troy Edward Wilson Director | Jun 11, 2026 | Award | +27,000 | – | – | 70,550 |
| Michael Patrick Miller Director | Jun 11, 2026 | Award | +27,000 | – | – | 81,000 |
| Alessandra Cesano Director | Jun 11, 2026 | Award | +27,000 | – | – | 68,850 |
| Maximo F. Nougues Chief Financial Officer | Feb 18, 2026 | Award | +46,739 | – | – | 240,023 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Feb 18, 2026 | Award | +159,778 | – | – | 7,305,729 |
| Douglas M. Hunt See Remarks | Feb 18, 2026 | Award | +49,394 | – | – | 205,301 |
| Douglas M. Hunt See Remarks | Jan 7, 2026 | Sale(10b5-1 plan) | −5,014 | $5.88 | $29.48K | 155,907 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jan 7, 2026 | Sale(10b5-1 plan) | −18,012 | $5.88 | $105.91K | 7,145,951 |
| Maximo F. Nougues Chief Financial Officer | Jan 7, 2026 | Sale(10b5-1 plan) | −6,405 | $5.88 | $37.66K | 193,284 |
| Douglas M. Hunt See Remarks | Jan 6, 2026 | Sale(10b5-1 plan) | −3,973 | $5.84 | $23.20K | 160,921 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jan 6, 2026 | Sale(10b5-1 plan) | −16,938 | $5.84 | $98.92K | 7,163,963 |
| Maximo F. Nougues Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −4,540 | $5.84 | $26.51K | 199,689 |
| Michael Patrick Miller Director | Nov 11, 2025 | Sale | −20,000 | $4.86 | $97.20K | 54,000 |
| Alessandra Cesano Director | Jul 18, 2025 | Sale(10b5-1 plan) | −27,000 | $3.37 | $90.99K | 41,850 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jul 9, 2025 | Sale(10b5-1 plan) | −21,580 | $3.54 | $76.39K | 7,180,901 |
| Douglas M. Hunt See Remarks | Jul 9, 2025 | Sale(10b5-1 plan) | −3,443 | $3.54 | $12.19K | 164,894 |
| Maximo F. Nougues Chief Financial Officer | Jul 9, 2025 | Sale(10b5-1 plan) | −3,935 | $3.54 | $13.93K | 204,229 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jul 8, 2025 | Sale(10b5-1 plan) | −25,592 | $3.53 | $90.34K | 7,202,481 |
| Douglas M. Hunt See Remarks | Jul 8, 2025 | Sale(10b5-1 plan) | −4,374 | $3.53 | $15.44K | 168,337 |
| Maximo F. Nougues Chief Financial Officer | Jul 8, 2025 | Sale(10b5-1 plan) | −5,587 | $3.53 | $19.72K | 208,164 |
| Jay M. Moyes Director | Jun 13, 2025 | Sale(10b5-1 plan) | −22,000 | $3.40 | $74.80K | 53,322 |
| Brian M. Stuglik Director | Jun 13, 2025 | Sale(10b5-1 plan) | −8,100 | $3.39 | $27.46K | 94,958 |
| Allison Dorval Director | Jun 13, 2025 | Sale(10b5-1 plan) | −11,610 | $3.40 | $39.47K | 75,390 |
| Adrian Senderowicz Director | Jun 13, 2025 | Sale(10b5-1 plan) | −27,000 | $3.40 | $91.80K | 27,000 |
| Troy Edward Wilson Director | Jun 13, 2025 | Sale(10b5-1 plan) | −10,800 | $3.40 | $36.72K | 43,550 |
| Alessandra Cesano Director | Jun 13, 2025 | Sale(10b5-1 plan) | −12,150 | $3.40 | $41.31K | 68,850 |
| Michael Patrick Miller Director | Jun 11, 2025 | Award | +27,000 | – | – | 74,000 |
| Jay M. Moyes Director | Jun 11, 2025 | Award | +27,000 | – | – | 75,322 |
| Troy Edward Wilson Director | Jun 11, 2025 | Award | +27,000 | – | – | 54,350 |
| Allison Dorval Director | Jun 11, 2025 | Award | +27,000 | – | – | 87,000 |
| Alessandra Cesano Director | Jun 11, 2025 | Award | +27,000 | – | – | 81,000 |
| Adrian Senderowicz Director | Jun 11, 2025 | Award | +27,000 | – | – | 54,000 |
| Brian M. Stuglik Director | Jun 11, 2025 | Award | +27,000 | – | – | 103,058 |
| Douglas M. Hunt See Remarks | Feb 7, 2025 | Award | +48,117 | – | – | 172,711 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Feb 7, 2025 | Award | +198,399 | – | – | 7,228,073 |
| Maximo F. Nougues Chief Financial Officer | Feb 7, 2025 | Award | +61,456 | – | – | 213,751 |
| Jeffrey Jerome Ludwig Chief Commercial Officer | Feb 7, 2025 | Award | +47,841 | – | – | 156,792 |
| Jeffrey Jerome Ludwig Chief Commercial Officer | Jan 2, 2025 | Sale(10b5-1 plan) | −9,437 | $3.15 | $29.73K | 108,951 |
| Douglas M. Hunt See Remarks | Jan 2, 2025 | Sale(10b5-1 plan) | −8,633 | $3.15 | $27.19K | 124,594 |
| Maximo F. Nougues Chief Financial Officer | Jan 2, 2025 | Sale(10b5-1 plan) | −10,227 | $3.15 | $32.22K | 152,295 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jan 2, 2025 | Sale(10b5-1 plan) | −33,841 | $3.15 | $106.60K | 7,029,674 |
| Michael Patrick Miller Director | Aug 12, 2024 | Sale | −23,358 | $3.49 | $81.52K | 47,000 |
| Alan H. Auerbach President and CEO, Director, 10% owner | Jul 17, 2024 | Sale(10b5-1 plan) | −21,920 | $3.70 | $81.10K | 7,063,515 |
| Douglas M. Hunt See Remarks | Jul 17, 2024 | Sale(10b5-1 plan) | −3,637 | $3.70 | $13.46K | 133,227 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Puma Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 681 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Alessandra Cesano Director | Sep 14, 2026 | 62,150 | $565.57K | Sep 14, 2026 | Restricted Stock Vesting |
| Troy Edward Wilson Director | Sep 14, 2026 | 5,000 | $45.50K | Sep 14, 2026 | Restricted Stock Vesting |
| Alan H. Auerbach Officer, Director | Jul 6, 2026 | 44,058 | $364.04K | Jul 6, 2026 | Restricted Stock Vesting |
| Douglas M. Hunt Officer | Jul 6, 2026 | 8,460 | $69.90K | Jul 6, 2026 | Restricted Stock Vesting |
| Maximo F. Nougues Officer | Jul 6, 2026 | 9,386 | $77.55K | Jul 6, 2026 | Restricted Stock Vesting |
| Adrian Senderowicz Director | Jun 12, 2026 | 27,000 | $196.02K | Jun 12, 2026 | Restricted Stock Vesting |
| Troy Edward Wilson Director | Jun 12, 2026 | 10,800 | $78.41K | Jun 12, 2026 | Restricted Stock Vesting |
| Brian M. Stuglik Director | Jun 12, 2026 | 8,100 | $58.81K | Jun 12, 2026 | Restricted Stock Vesting |
| Allison Dorval Director | Jun 12, 2026 | 11,610 | $84.29K | Jun 12, 2026 | Restricted Stock Vesting |
| Jay M. Moyes Director | Jun 12, 2026 | 22,000 | $159.72K | Jun 12, 2026 | Restricted Stock Vesting |
| Maximo F. Nougues Officer | Jan 7, 2026 | 6,405 | $37.66K | Jan 7, 2026 | Restricted Stock Vesting |
| Douglas M. Hunt Officer | Jan 7, 2026 | 5,014 | $29.48K | Jan 7, 2026 | Restricted Stock Vesting |
| Alan H. Auerbach Officer, Director | Jan 7, 2026 | 18,012 | $105.89K | Jan 7, 2026 | Restricted Stock Vesting |
| Douglas M. Hunt Officer | Jan 6, 2026 | 3,973 | $23.22K | Jan 6, 2026 | Restricted Stock Vesting |
| Alan H. Auerbach Officer, Director | Jan 6, 2026 | 16,938 | $98.98K | Jan 6, 2026 | Restricted Stock Vesting |
Congress trades
7 trades in Puma Biotechnology reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Donna Shalala FL27 | Sold | May 15, 2019 | $1K–15K | Apr 27, 2020 348 days late |
| Donna Shalala FL27 | Bought | Jan 23, 2019 | $1K–15K | Apr 27, 2020 460 days late |
| Nick J. Rahall II WV03 | Sold | Sep 26, 2014 | $1K–15K | Oct 13, 2014 |
| Nick J. Rahall II WV03 | Bought | Sep 10, 2014 | $1K–15K | Oct 13, 2014 |
| Nick J. Rahall II WV03 | Bought | Jul 30, 2014 | $1K–15K | Aug 14, 2014 |
| Nick J. Rahall II WV03 | Bought | Jul 24, 2014 | $15K–50K | Aug 14, 2014 |
| Nick J. Rahall II WV03 | Sold | Jul 23, 2014 | $15K–50K | Aug 14, 2014 |
See a number that looks wrong?